Forecast
The analysts' average price target is €1.82 (-6.67%). The median is €1.82 (-6.67%).
| Buy |
Â
8 |
| Hold |
Â
4 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Accuray reports mixed Q4 results: revenue weaker, stock under pressure
Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » More on de.investing.com
Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence
Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » More on de.investing.com
Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs
Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » More on de.investing.com
Accuray reports 12% revenue decline in Q2 FY26 and lowers full-year guidance
Accuray reported Q2 FY26 revenue of $102.2 million (-12%), with product revenue down 26% to $45.0 million and service revenue up 4% to $57.2 million. Gross margin fell to 23.5% and adjusted EBITDA declined to -$1.9 million. Shipments through the China joint venture dropped sharply (11 vs. 27 units), weighing on reporting and margins. The company cut its full-year guidance to $440–450 million in revenue and $22–25 million in adjusted EBITDA, and plans $13 million in restructuring charges and a 15% workforce reduction. » More on de.investing.com
Accuray: board member Byron C. Scott to resign effective December 31, 2025
Byron C. Scott has announced his resignation from Accuray’s board of directors, effective December 31, 2025. In a filing with the SEC, the company said the resignation is not due to any disagreements with Accuray or its boards. No other changes to the board or management were disclosed. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2022, Accuray has already paid €0.62 in dividends. The last payout was in June 2022.
Financials
In the last quarter, Accuray had revenue of €76.39m and net profit of €8.95m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 76.39m | 4.58% |
| Gross profit | 23.03m | 1.79% |
| Net profit | 8.95m | 148.43% |
| EBITDA | 19.85m | 302.89% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.83m |
Number of shares | 3m |
52-week high/low | €41.19 - €2.17 |
| Dividends | No |
Beta | 1.38 |
P/E ratio | -0.43 |
PEG ratio | 0.01 |
P/B ratio | 0.16 |
P/S ratio | 0.02 |
Company profile
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
| Name | Accuray |
| CEO | Stephen R. LaNeve |
| Headquarters | Madison,
wi USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 08/02/2007 |
| Employees | 809 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ARAY |
London Stock Exchange | 0H8I.L |
Frankfurt | XEJ.F |
DĂĽsseldorf | XEJ.DU |
London | 0H8I.L |
SIX | XEJ.SW |
MĂĽnchen | XEJ.MU |